Strategies to control T2D can be achieved by use of oral agents that acts with different mechanisms such as insulin secretagogues and sensitizers [3], inhibitors of dipeptidyl peptidase IV (DPP-IV) [4], α-glucosidase [5], SGLT2 [6], and glycogen phosphorylase α (GP-α). The gene discussed is GYPA; the disease is type 2 diabetes mellitus.